Expanding therapeutic options for people with NF2-related schwannomatosis: Encouraging results with brigatinib
Neuro Oncol
.
2024 Nov 4;26(11):1949-1950.
doi: 10.1093/neuonc/noae137.
Authors
Scott R Plotkin
1
,
Jaishri O Blakeley
2
Affiliations
1
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
2
Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.
PMID:
39389170
PMCID:
PMC11534312
DOI:
10.1093/neuonc/noae137
No abstract available
Grants and funding
P30 CA006516/CA/NCI NIH HHS/United States
NIH 5 P30 CA06516/Andrea Cahill Foundation
Takeda Pharmaceuticals